Solbec progresses psoriasis trial
Tuesday, 05 October, 2004
Solbec Pharmaceuticals (ASX:SBP) has completed the first stage of its Phase I clinical trial for a psoriasis treatment based on its lead drug candidate SBP002.
The drug, formulated as a cream, was tested on a number of healthy individuals with no unwanted effects or reactions recorded. The company will now move on to test the treatment at a therapeutic dose, in preparation for larger Phase II trials, expected to commence after the Phase I trial winds up in early 2005.
The clinical trials are being conducted by clinical trials unit CMAX, part of listed Australian company IDT, in Adelaide.
SBP002 is also under investigation by Solbec as a cancer treatment for mesothelioma and melanoma.
Pancreatic cancer hijacks metabolism switch to help it spread
Pancreatic cancer hijacks a molecule known for regulating physiological processes, such as food...
Novel antibiotic activates 'suicide' mechanism in superbug
Researchers have discovered a new class of antibiotic that selectively targets Neisseria...
Modifications in the placenta linked to psychiatric disorders
Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...
